drugset / Trial / NCT00241527

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241527

Phase 3 Completed 556 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This study was a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs placebo and esomeprazole 20 mg orally qd vs placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a treatment period of 4 weeks for relief of upper GI symptoms.

Timeline

Start
2000-12
Primary completion
2002-09
Completion
2002-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg Oral
Subject Esomeprazole Small molecule 40 mg Oral